Pharmacy Benefits Management Services Home

Rivaroxaban is an oral, direct factor Xa inhibitor that is also FDA approved for the 1) prophylaxis of venous thromboembolism (VTE) in patients undergoing total hip replacement (THR) or total knee replacement (TKR) surgery and 2) prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). ................
................